Dr. Rabinovici is the Edward Fein and Pearl Landrith Distinguished Professor in the UCSF Departments of Neurology, Radiology & Biomedical Imaging. He received his BS degree from Stanford University and MD from Northwestern University. He completed neurology residency and behavioral neurology fellowship at UCSF. Dr. Rabinovici’s work investigates how structural, functional and molecular brain imaging techniques can be used to improve diagnostic accuracy in dementia and to study the biology of neurodegenerative diseases, with the goal of accelerating drug development. He is Director of the UCSF Alzheimer’s Disease Research Center, study chair of the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) and New IDEAS studies (~25,000 total participants), co-PI and PET Core lead of the Longitudinal Evaluation of Alzheimer’s Disease Study (LEADS), among other studies. His research is supported by NIH, Alzheimer’s Association, American College of Radiology, Rainwater Charitable Foundation, Weill Neurohub Alliance for Therapies in Neuroscience, additional foundations and industry partners. Previous awards include the 2022 Kuhl-Lassen Award from the Society for Nuclear Medicine and Molecular Imaging, 2015 Christopher Clark Award in Amyloid Imaging, the 2012 American Academy of Neurology Research Award in Geriatric Neurology and the 2010 deLeon Prize from the Alzheimer’s Association.

I am a PhD candidate at the University of Pittsburgh studying kinase networks that regulate tau pathogenesis in Alzheimer's Disease. Specifically, I have used post-mortem human brain, cell lines, and human-derived neurons to investigate cellular and molecular pathways governing tau aggregation.

Aura María Ramírez, PhD, is a dedicated research scientist, specializing in the biomedical field. With a Doctor of Philosophy in Interdisciplinary Biomedical Sciences from the University of Arkansas for Medical Sciences, a Master of Science in Biological Sciences from Pontificia Universidad Javeriana, and dual Bachelor of Science degrees in Biology and Microbiology from Universidad de los Andes. Currently serving as a Postdoctoral Associate at the Hussman Institute for Human Genomics in Miami, Florida, Aura's research focuses on identifying genes and their impact on the risk and outcomes associated with Alzheimer's disease.

Dr. Ramsden is the Chief of the Lipid Peroxidation Unit within the Laboratory of Clinical Investigation in the National Institute on Aging (NIA) and a CAPT in the Commissioned Corps of the U.S. Public Health Service. His Unit leverages expertise in brain lipids and lipoproteins to uncover molecular mechanisms and develop new treatments for chronic pain and Alzheimer’s disease. Dr. Ramsden received his B.S. in Biology from the University of Virginia, M.D. from the Medical College of Georgia, and Ph.D. from the University of Adelaide. Following completion of medical internship and residency, Dr. Ramsden was a clinical research fellow at UNC-Chapel Hill before joining the Intramural Program of the NIAAA as a Staff Clinician/Clinical Investigator in 2009. In 2016, he joined the NIA Laboratory of Clinical Investigation as a Tenure-Track Investigator in Baltimore, MD, with a joint appointment in the Intramural Program of NIAAA in Bethesda, MD.

Dr. Laura P.W. Ranum, is the Director of the Center for Neurogenetics and the Kitzman Family Professor of Molecular Genetics and Microbiology at the University of Florida. In 2011, her lab discovered that novel category of proteins are produced from repeat expansion mutations that do not require a canonical AUG-initiation codon for expression. These toxic, repeat-associated, non-AUG (RAN) proteins have been found in a growing number of neurodegenerative diseases including Huntington’s disease, amyotrophic lateral sclerosis, frontotemporal dementia, and ataxia. Recently, her lab identified a novel intronic GGGAGA repeat expansion associated with Alzheimer’s disease. Mechanistic insights from her recent work have identified novel therapeutic strategies to treat RAN protein disorders.

I received my PhD in Cognition and Neuroscience from the University of Texas at Dallas in 2021. I work at the Taub Institute for Research on the Aging Brain at Columbia University where I study genetic biomarkers of Alzheimer's Disease related to African ancestry.

Chris Reading received his Ph.D. in Biochemistry from UC Berkeley, performed post-doctoral studies in cancer biology at UC Irvine, and joined MD Anderson Cancer Center and the University of Texas, Graduate School of Biomedical Sciences in Houston for 13 years, where he became Associate Professor of Medicine in the Department of Developmental Therapeutics with a joint appointment in the Department of Tumor Biology. He then accepted a position at Systemix / Novartis in Palo Alto, where he became Vice President of Product and Process Development. From there, he moved to San Diego where he has spent over 15 years on the NE3107 platform development at Harbor Therapeutics. He has over 35 years of research and drug development experience, and over 130 peer-reviewed scientific publication, and has authored numerous patents in the areas of monoclonal antibodies, cell separation technologies, stem cell transplantation, and sterol drug development.

Department of Nuclear Medicine and PET, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.